drugset / Trial / NCT02851589
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Phase 1/2
Unknown
10 enrolled
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.
Timeline
- Start
- 2016-07
- Primary completion
- 2018-11
- Completion
- 2019-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PCAR-019 | Cell therapy | — | Other |